Skip to content
Friday, March 24, 2023
HealthCare Middle East & Africa Logo 500

No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa

  • HOME
  • TOPICS
    • MERGERS, INVESTMENTS & FUNDING
    • DISEASES UPDATES
    • HOSPITALS
    • PHARMACEUTICALS
    • PEOPLE NEWS
  • THE MAGAZINE
    • About HealthCare Middle East & Africa Magazine
    • PRESS RELEASES
    • SUBSCRIBE TO EMAIL NEWSLETTERS
  • ADVERTISE
  • PROFILES & INTERVIEWS
  • OUR EVENTS
  • CONTACT US
BREAKING NEWS
  • UAE-based AstraGene and Mylab form joint venture to commercialize automated diagnostics
  • Chinese missionaries in Rwanda perform painless normal delivery
  • <strong>OSHCO, VAMED Group to establish a new rehabilitation & long-term care hospital in Riyadh</strong>
  • Uganda launches project to scale up paediatric surgical services in hospitals
  • <strong>Dubai’s state-owned DAHC, Pfizer, AXDEV Group ally to enhance chronic illness care</strong>
  • Macra supports Ministry of Health with US$53,296 cholera materials
  • KFSH&RC to debut its Digital Health Conference in Riyadh
  • NPHCDA launches project to prevent maternal health challenges
  • <strong>Saudi’s KAEC inks health cooperation pact with Dr. Sulaiman Al Habib Medical Group</strong>
  • Africa has the highest global surge in oral diseases - WHO
You are here
  • Home
  • US FDA

Tag: US FDA

FDA removes most doses of Ozempic from drug shortage list after Novo Nordisk resolves supply issues

21 March 202322 March 2023

USA — Novo Nordisk’s Ozempic, a treatment for type 2 diabetes and off-label for weight loss, is no longer on the FDA’s drug shortage list after months of limited supply.…

Read More

FDA advisory panel supports full approval of Pfizer’s COVID therapy

17 March 202317 March 2023

USA —Advisers to the U.S. Food and Drug Administration gave strong support for full approval of Pfizer’s oral antiviral COVID-19 treatment, Paxlovid, for adults at high risk of severe disease…

Read More

Pfizer’s Zavzpret nasal spray granted FDA approval for migraine treatment

14 March 202314 March 2023

USA — The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Zavzpret (zavegepant) for the acute treatment of migraine in adult patients with or without aura. As the first…

Read More

Glenmark, Cediprof ink distribution pact for prescription drugs in the US

9 March 20239 March 2023

INDIA – Glenmark Pharmaceuticals and Cediprof, Inc. have entered into an exclusive supply and distribution agreement for the latter’s prescription drugs in the United States. Glenmark’s current portfolio consists of…

Read More

Revolutionary concussion detection blood test from Abbott receives FDA approval

9 March 202310 March 2023

USA— Abbott has received clearance from the U.S. Food and Drug Administration (FDA) for the first commercially available laboratory test for traumatic brain injury (TBI), which will be widely accessible…

Read More

Sun Pharma’s acquisition of Concert fuels hopes of deuruxolitinib push to FDA Drug Review

7 March 20238 March 2023

INDIA – Sun Pharma has wrapped up the acquisition of Concert Pharmaceuticals Inc. (Concert) with the desire to accelerate the market entry of deuruxolitinib, a potential best-in-class treatment for alopecia…

Read More

FDA encourages adoption of continuous manufacturing to build a resilient pharma sector

6 March 20237 March 2023

USA — The FDA has issued final guidance on the use of continuous manufacturing in drug production, aimed at easing the industry’s transition to these advanced processes. The guidelines cover…

Read More

FDA advisory panel to assess broader application of Merck-AstraZeneca cancer medication

5 March 20236 March 2023

USA —Merck & Co Inc and AstraZeneca have announced that an independent committee of advisers to the U.S. Food and Drug Administration (FDA) will evaluate their application for the expanded…

Read More

FDA approves once-weekly hemophilia drug from Sobi and Sanofi

24 February 202324 February 2023

USA — The U.S. Food and Drug Administration (FDA) has granted approval for a new hemophilia treatment co-developed by Sanofi and Sobi that has the potential to offer greater convenience…

Read More

U.S. and EU regulators to expedite reviews of Pfizer’s RSV vaccine

22 February 202322 February 2023

USA — Pfizer has announced that regulatory authorities in the US and Europe have accepted marketing applications for its RSVpreF vaccine candidate for respiratory syncytial virus (RSV), with decisions expected…

Read More

Posts navigation

Older posts

LATEST DIGITAL MAGAZINE

LATEST NEWS

  • UAE-based AstraGene and Mylab form joint venture to commercialize automated diagnostics
  • Chinese missionaries in Rwanda perform painless normal delivery
  • OSHCO, VAMED Group to establish a new rehabilitation & long-term care hospital in Riyadh
  • Uganda launches project to scale up paediatric surgical services in hospitals
  • Dubai’s state-owned DAHC, Pfizer, AXDEV Group ally to enhance chronic illness care

MOST POPULAR TAGS

Africa Africa CDC Artificial Intelligence AstraZeneca Cancer Covid-19 Diabetes Digital health Egypt France Germany Ghana GSK Healthcare Delivery HIV/AIDS Hospitals India Japan Johnson & Johnson Kenya Malaria Merck Mergers, Investments & Funding Middle East and North Africa Moderna MOH Kenya Nigeria Novartis Partnerships Pfizer Pharmaceuticals Public Health Roche Science & Technology South Africa Switzerland Tanzania UAE Uganda UK UNICEF USA US FDA Vaccines WHO

ARCHIVES

ABOUT FW AFRICA

We organise some of the most impactful face to face and virtual trade events and publish leading magazines and websites that bring Africa to the World and the World to Africa. We believe that when people come together, networks grow and businesses thrive.

Find more about us on our corporate website www.fwafrica.net

RELATED PUBLICATIONS

CEO Business Africa

Food Business Africa

Food Safety Africa

Milling & Baking Africa

Sustainable Packaging Africa

CONTACT US

FW Africa

P.O. Box 1874-00621, Nairobi, Kenya

Tel: +254 725 34 39 32

Email: info@fwafrica.net

Copyright © All rights reserved. FW Africa. We are not responsible for content from external sites.